249 related articles for article (PubMed ID: 31268724)
1. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
2. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates.
Aneheim E; Gustafsson A; Albertsson P; Bäck T; Jensen H; Palm S; Svedhem S; Lindegren S
Bioconjug Chem; 2016 Mar; 27(3):688-97. PubMed ID: 26791409
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
[TBL] [Abstract][Full Text] [Related]
7. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.
Choi J; Vaidyanathan G; Koumarianou E; McDougald D; Pruszynski M; Osada T; Lahoutte T; Lyerly HK; Zalutsky MR
Nucl Med Biol; 2014; 41(10):802-12. PubMed ID: 25156548
[TBL] [Abstract][Full Text] [Related]
8. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
9. Labeling single domain antibody fragments with
Zhou Z; McDougald D; Meshaw R; Balyasnikova I; Zalutsky MR; Vaidyanathan G
Nucl Med Biol; 2021; 100-101():24-35. PubMed ID: 34146837
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
[TBL] [Abstract][Full Text] [Related]
12. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
[TBL] [Abstract][Full Text] [Related]
14.
D'Huyvetter M; De Vos J; Xavier C; Pruszynski M; Sterckx YGJ; Massa S; Raes G; Caveliers V; Zalutsky MR; Lahoutte T; Devoogdt N
Clin Cancer Res; 2017 Nov; 23(21):6616-6628. PubMed ID: 28751451
[No Abstract] [Full Text] [Related]
15. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
[TBL] [Abstract][Full Text] [Related]
16. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Efficacy of
Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
[TBL] [Abstract][Full Text] [Related]
18. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy.
Lindegren S; Andersson H; Jacobsson L; Bäck T; Skarnemark G; Karlsson B
Bioconjug Chem; 2002; 13(3):502-9. PubMed ID: 12009939
[TBL] [Abstract][Full Text] [Related]
20. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]